Trade-Ideas: Mylan (MYL) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Mylan ( MYL) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Mylan as such a stock due to the following factors:

  • MYL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $160.9 million.
  • MYL is up 2.8% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MYL with the Ticky from Trade-Ideas. See the FREE profile for MYL NOW at Trade-Ideas

More details on MYL:

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. MYL has a PE ratio of 31.0. Currently there are 9 analysts that rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Mylan has been 4.1 million shares per day over the past 30 days. Mylan has a market cap of $18.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.16 and a short float of 7.3% with 9.72 days to cover. Shares are up 16.8% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids